Meeting
2020 ASCO Virtual Scientific Program
Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C), and paricalcitol (P)neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).
Presenter
Erkut Hasan Borazanci, MD, MS
HonorHealth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT03138720
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4631)
DOI
10.1200/JCO.2020.38.15_suppl.4631
Abstract #
4631
Poster Bd #
239
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).
Speaker: Gayle S. Jameson, AOCN, MSN, NP
Videos & Slides
2020 Gastrointestinal Cancers Symposium
A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.
Speaker: Eileen Mary O'Reilly, MD
Speaker: To Be Determined
Videos & Slides
2024 ASCO Annual Meeting
A prospective multicenter trial of dose escalation for weekly gemcitabine concurrent with intensity-modulated radiotherapy following cisplatin and gemcitabine induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma.
Speaker: Qi Zeng, MD, PhD